AllSight
Companies · EVMN · Pharmaceutical Preparations

Evommune, Inc. (EVMN)

Evommune, Inc. (EVMN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Evommune, Inc. (EVMN) stock — financials & valuation

Key numbers for Evommune, Inc. (EVMN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 53/100 — a percentile rank of Evommune, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$303.0M
P / S30.3×
EV / EBITDA-2.4×
Return on equity-34.1%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Evommune, Inc.’s own financial statements and shown as context, never as advice.

Oct 1, 2026Above the bar
Evommune Phase 2a data clears AD efficacy bar, but Phase 2b waits until 2027
Sep 23, 2026No new info
Evommune to unveil EVO301 Phase 2a data at EADV after EVO756 AD failure
Sep 15, 2026Pipeline reprioritized
Evommune’s updated deck pivots after EVO756 AD failure toward EVO301 and migraine
Sep 8, 2026Below the bar
Evommune's EVO756 misses every AD endpoint, forcing a pipeline reset
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact